HOOK News and Press, HOOKIPA Pharma Inc. From 06/25/21

The following slide deck was published by HOOKIPA Pharma Inc. in conjunction with this event. For further details see: HOOKIPA Pharma (HOOK) Investor Presentation -Sildeshow

Today, we revisit HOOKIPA Pharma for the first time in more than a year and a half. The company aims to develop a novel class of immunotherapeutics targeting infectious diseases and cancers based on their proprietary arenavirus platform that works by reprogramming the body's immune sy...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks ended the day and the week modestly higher Friday, as investors shrugged off a report showing inflation in the U.S. rising 5%, its fas...

NEW YORK and VIENNA, Austria, June 10, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will partic...

Photo by tolgart/iStock via Getty Images Having lost more than a fifth of its value yesterday, HOOKIPA Pharma ([[HOOK]] -16.8%) is continuing the slide in reaction to the company’s updated data from the Phase 1/2 study for HB-200 in the treatment of advanced Human Papillomavirus 1...

Gainers: Clover Health Investments CLOV +70%, Precipio PRPO +15%, GBS (GBS) +15%, PDS Biotechnology PDSB +15%, Cyclerion Therapeutics CYCN +10%.Losers: Ra Medical Systems RMED -19%, HOOKIPA Pharma HOOK -15%, AC Immune (ACIU...

HOOKIPA Pharma (HOOK) has reported positive Phase 1 data from its ongoing Phase 1/2 study of HB-200 for the treatment of advanced Human Papillomavirus 16-positive (HPV16+) cancers.Up to the March 31 cut-off date, 38 patients with metastatic HPV16+ tumors had received HB-200 therapy: 14 receiv...

Novel arenaviral therapeutic HB-200 generates outstanding tumor antigen-specific CD8+ T cell responses (average of 6 percent and up to 40 percent of T cell pool) To-date, HB-201 monotherapy has shown 18 percent overall response rate and median progression-free survival of 3.45 mon...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Gainers: Big Rock Partners Acquisition (BRPA) +86%.Euro Tech Holdings (CLWT) +32%.Urban One (UONE) +28%.Sensei Biotherapeutics (SNSE) +28%.BBQ Holdings (BBQ) +22%.PDS Biotechnology (PDSB) +20%.Advanced Emissions Solutions (ADES) +19%.Progenity (PROG) +18%.Moxian (MOXC) +16%.Precipio (PRP...